Hugel expects to begin distributing its wrinkle-smoothening botulinum toxin in the $1 billion European market in mid-2021, the company announced Tuesday. Hugel and its European distribution partner, Croma Pharma, have successfully completed phase 3 clinical trials in January 2019 and completed the submission of New Drug Application with the European Medicines Agency on Monday. As the standard review process takes roughly a year, Hugel expects to receive the approval in mid-2021. “Eur

We know this by many names. Poo, feces, stool, turd, excrement. ... The list can grow endless if imaginative children join in. But scatology is not a matter to be lightly regarded, as “gut feelings” take on a literal meaning in health care. Chunlab, a microbiome research firm, on Tuesday launched three-step services analyzing feces for personalized health care. Chunlab’s Gut Inside survey collects excrement in a bag and analyzes the beneficial and harmful bacteria found in i

Korean information technology firm NHN said Monday it has launched an automated in-hospital messenger service setting out to streamline medical professionals’ workflow. The system is optimal for cases where medical professionals from several disciplines have to collaborate, NHN said. TOAST MedicalTalk will first be applied at Severance Hospital in Yongin, Gyeonggi Province. The communication tool aids medical professionals in delivering patient-centered treatment. It combines the preexi

LabGenomics, a molecular diagnostics health care company, developed the world’s first 35-minute real-time polymerase chain reaction test kit for COVID-19. The company’s shares, listed on the tech-heavy Kosdaq, hit the daily growth ceiling of 30 percent on the day of the announcement Wednesday and continued to be upbeat in early morning trading Thursday, rising by 14.17 percent. Before, RT-PCR test kits for COVID-19 could yield results as fast as 2 1/2 hours. LabGenomics’ 35

Novel drugs developer Hanmi Science vowed Thursday to rev up its engine for Cydio Cigma -- six goals, standing for cyber education, digital bio, oral bio, city bio, green bio and marine Bio. “Where there is no innovation, there is no development. Those who turn their backs on challenges are branded as cowards. Cydio Cigma is our goal and commitment for the post-COVID-19 era,” said Hanmi Science CEO Lim Chong-yoon at a meeting with executives in June. Lim promised to reward employe

Investors were highly enthusiastic about the initial public offering of SK Biopharmaceuticals in the two-day retail tranche that wrapped up Wednesday, as it was oversubscribed 323 times with deposit payments amounting to 30.98 trillion won ($25.8 billion). The deposit payments -- 50 percent of the offering price -- reached 19.5 trillion won by noon and then zoomed up, according lead underwriter NH Investment & Securities. The drugmaker specializes in developing novel medicines for central

  진행: 임정요, Kevin Lee Selzer 1. Leafleting: decisive propaganda or empty provocation? 아이튠즈(아이폰): https://itunes.apple.com/kr/podcast/koliaheleoldeu-paskaeseuteu/id686406253?mt=2 팟빵 (안드로이드): http://www.podbbang.com/ch/6638 [1] Even in the 21st century with all its technical wizardry and social media, old-fashioned propaganda leaflets seem to matter a great deal on Korean Peninsula, the world’s last remaining Cold War frontier. *wizardry: 마법 *social media: SNS *old-fashioned: 고전적인

Samsung Biologics shares started upbeat Wednesday morning, up 2.62 percent from a day before, in light of its disclosure that it has nabbed a contract manufacturing deal worth $314 million with a European biopharmaceutical firm. The size of this new deal is as big as 54.3 percent the company’s revenue in 2019 at 701.6 billion won ($582 million). Combined with two other deals inked earlier in June, Samsung Biologics has already achieved 95.57 percent of last year’s revenue in the f

Celltrion shares rose 7.58 percent on Tuesday, following news that an Italian COVID-19 patient tested negative for the virus a week after being treated with Celltrion’s autoimmune disease treatment Remsima. Celltrion Healthcare, the global distributing arm of biologics drug manufacturer Celltrion, said that a patient in an Italian national hospital in Milan who had symptoms of pneumonia due to SARS CoV-2 infection, was treated with Remsima, and was discharged a week later after recovery.

Boryung Pharmaceutical presented the outcomes of the preclinical tests of its innovative blood cancer treatment on Tuesday at the American Association for Cancer Research, saying that the BR101801 pipeline showed more potency than existing phosphoinositide 3-kinase drugs in animal models. BR101801, a targeted cancer treatment and immuno-oncology drug that is being independently studied by Boryung Pharmaceutical, can simultaneously suppress the activities of PI3K and DNA-dependent protein kinase

Biologics companies are receiving more investor attention than ever due to the COVID-19 pandemic. But the question remains if the sudden buoyance is a bubble that can burst at any moment. Among the publicly traded Korean biologics companies, market watchers are especially eyeing Samsung Biologics, Celltrion and soon-to-be listed SK Biopharmaceuticals. Samsung Biologics shares especially soared past the 800,000 won ($660) after the Seoul Central District Court denied an arrest warrant for Samsu

South Korea’s SD Biotechnologies is rapidly fueling its business overseas through online and offline channels, according to officials. The beauty and health care company boasts six growing brand lines -- skin care brand SNP, standing for “shining,” “nature” and “purity”; colored makeup cosmetics brand Celebeau; urban pollution-tackling dermatologic cosmetic brand hddn=lab; professional barber grooming brand for men M’Solic; organic cotton-covered

　Cord blood-originated stem cell therapeutics firm Medipost’s CEO Yang Yoon-sun recounts 20 years of her entrepreneurship as being dotted with incessant challenges. 　Her journey as a professor of pathology at Samsung Medical Center to head of a cord blood stem cell research company at the age of 37 came with prejudices, challenges and pitfalls, but also with encouragement, conviction and immense potential. 　Cord blood is that inside the umbilical cord that connects the baby and mother

South Korea’s Chong Kun Dang presented its latest study results of the bispecific antibody pipeline CKD-702 that simultaneously inhibits c-Met and epidermal growth factor (EGFR) in animals who have grown resistant to existing tyrosine kinase inhibitors, at the online American Association of Cancer Research Annual Meeting 2020 that kicked off Monday. The CKD-702, currently being developed to treat non-small cell lung cancer in Korea, was tested on animals in single administrations to test

　SK Biopharmaceuticals, a novel drug research and development company specializing in the diseases pertaining to the central nervous system, has set its initial public offering price at 49,000 won ($40) per share, it said Friday. 　The company announced that this is the top end of its indicative price range, which had suggested the share price would be between 36,000 won and 49,000 won. 　This puts the total public offering value of SK Biopharmaceuticals at 959.3 billion won, with the market c

Medical artificial intelligence solution provider Vuno said Friday it plans to tap the Japanese market through Sony’s subsidiary M3. M3 is 33.9 percent owned by Sony and is Japan’s biggest medical data platform company with 280,000 medical professionals enrolled as members. It has accumulated knowledge in the conservative Japanese medical field, and provides a wide range of services including clinical test designing, marketing support for pharmaceutical firms and remote medicine.

“I purple you,” Samsung Galaxy S20+ BTS Edition, is selling like hot cakes. Preorders for Samsung Electronics’ Galaxy S20+ 5G phone and wireless earphones Buds+ BTS Editions, garbed in the K-pop group’s iconic purple and accentuated with tiny purple hearts and BTS logo, closed in an hour since opening in South Korea, Friday. The set is priced at 1.6 million won ($1,320), not a far-off figure from the combined price of a regular S20+ and Buds+, which cost about 1.5 milli

US-based Psomagen and Korean probiotics company Cell Biotech said Friday they will jointly strive for big data-based microbiome research and commercialization. According to the memorandum of understanding, Psomagen and Cell Biotech will research microbial organisms that will show clinical efficacy in health care, as well as develop new probiotics products. Using Psomagen’s big data analysis technology, they will identify potential novel drug materials and develop probiotics products sp

South Korea’s first botulinum toxin product Meditoxin has been stripped of its license, as of Thursday, in a blow dealt by the Drug Ministry against the company’s use of unauthorized substances in the botulinum toxin products manufactured between 2012 and 2015. Meditoxin, the BTX product accountable for 42 percent of Medytox’s yearly revenue in 2019, had been suspended of production and sales since April 17. It will lose the sales permit altogether from June 25, the Drug Minis

Chong Kun Dang said Thursday its anti-coagulant drug Nafabeltan (nafamostat) is to carry out clinical phase 2 trials to be repurposed as a COVID-19 treatment. The company said in a joint press release with Institut Pasteur Korea and Korea Institute of Radiological & Medical Sciences that Nafabeltan has demonstrated strong antiviral qualities against COVID-19 in a cellular-level test. Instiut Pasteur Korea had explored the antiviral qualities of over 3,000 molecules of which it found that